New hope for Hard-to-Treat myeloma: drug cocktail shows promise
NCT ID NCT04764942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of drugs (selinexor, pomalidomide, dexamethasone, and sometimes carfilzomib) in 39 adults with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combo controls the cancer. This is not a cure, but aims to manage the disease and shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?